Key Highlights

  • Sera Prognostics (NASDAQ:SERA) reported a third-quarter 2026 net loss of USD 8.05 million, or USD 0.16 per share, compared with USD 7.81 million a year earlier, on Revenue of USD 42 thousand versus USD 16 thousand.
  • Total operating expenses were USD 8.93 million, essentially flat against USD 9.00 million, as Research and Development fell to USD 2.72 million from USD 3.28 million.
  • Selling and Marketing expense rose to USD 2.25 million from USD 1.59 million as the company continued hiring in its commercial organization and spent more on marketing materials.
  • The company held USD 72.8 million in cash, equivalents and marketable securities combined (calculated), and its accumulated Deficit reached USD 337.3 million at September 30, 2026.

Revenue Remains Tiny as the Company Shifts to Commercial Sales

Sera Prognostics (NASDAQ:SERA) filed its Quarterly Report on November 4, 2026, for the three months ended September 30. Revenue was USD 42 thousand against USD 16 thousand, and cost of revenue was USD 61 thousand, so the test does not yet cover its direct cost. The company develops the PreTRM proteomic blood test, which is designed to assess preterm birth risk during pregnancy. It describes a transition from a clinical-stage company to a commercial organization focused on reimbursement-driven sales of PreTRM. Operating loss was USD 8.89 million, almost unchanged from USD 8.98 million, and other income, net, fell to USD 0.84 million from USD 1.17 million on lower interest income.

Restructuring Redirects Spending Toward Selling and Marketing

In May 2026 the company announced a restructuring that cut 14 full-time employees, about 18% of its workforce, with estimated severance costs of USD 1.3 million recognized in the second quarter. The aim was to move Capital away from research and general administration toward commercialization. The effect shows in the quarter. Research and development fell USD 0.56 million, with research and bioinformatics down USD 0.50 million and laboratory operations down USD 0.22 million. Selling and marketing rose USD 0.66 million, including USD 0.4 million for marketing materials and programs. General and administrative expense dipped USD 0.19 million as a USD 0.6 million fall in personnel costs offset USD 0.4 million of severance. For nine months, the net loss was USD 25.6 million against USD 24.0 million.

Cash Runway, Accumulated Deficit and Reimbursement Risk

The Balance Sheet showed USD 3.99 million of cash and equivalents, USD 40.10 million of current marketable securities and USD 28.74 million of long-term marketable securities, down from USD 101.9 million of total Assets at the end of 2025 to USD 80.0 million (calculated from the balance sheet). Management believes existing cash and cash equivalents will fund operating expenses and capital needs for at least 12 months. The filing warns that losses may continue to grow as Sera Prognostics (NASDAQ:SERA) works to raise adoption of, and reimbursement for, PreTRM. Revenue of USD 42 thousand shows commercial adoption is at an early stage. The material reviewed gives no guidance, consensus or share price move.

Where Things Stand

Because commercial sales have barely started while a research-era cost base remains. Sera Prognostics (NASDAQ:SERA) lost USD 8.05 million in the quarter on USD 42 thousand of revenue, and spending is only being reshuffled, not cut, with operating expenses flat at USD 8.93 million. Cash and marketable securities of about USD 72.8 million (calculated) fund the plan for at least 12 months by management's view. Next markers are adoption and reimbursement for the PreTRM test, quarterly revenue growth, further selling and marketing spend and the pace of cash use.